Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 201 of the 202 references it cites were found in a registry or an index.

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

Buscail, Louis, Bournet, Barbara, Cordelier, Pierre · 2020 · Nature Reviews Gastroenterology & Hepatology

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common cause of death within the next 10 years. The prognosis for this disease is poor despite diagnostic progress and new chemotherapeutic regimens. The oncogenic KRAS mutation is the major event in pancreatic cancer; it confers permanent activation of the KRAS protein, which acts as a molecular switch to activate various intracellular signalling pathways and transcription factors inducing cell proliferation, migration, transformation and survival. Several laboratory methods have been developed to detect KRAS mutations in biological samples, including digital droplet PCR (which displays high sensitivity). Clinical studies have revealed that a KRAS mutation assay in fine-needle aspiration material combined with cytopathology increases the sensitivity, accuracy and negative predictive value of cytopathology for a positive diagnosis of pancreatic cancer. In addition, the presence of KRAS mutations in serum and plasma (liquid biopsies) correlates with a worse prognosis. The presence of mutated KRAS can also have therapeutic implications, whether at the gene level per se, during its post-translational maturation, interaction with nucleotides and after activation of the various oncogenic signals. Further pharmacokinetic and toxicological studies on new molecules are required, especially small synthetic molecules, before they can be used in the therapeutic arsenal for pancreatic ductal adenocarcinoma.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0245-4

Cites

201 of 201 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 202 references

Research works printed but not linked: 1

  1. Mandel, P. & Metais, P. Les acides nucleiques du plasma sanguin chez l’homme [French]. C. R. Seances Soc. Biol. Fil. 142, 241–243 (1948).

Cited by

See all 762

Metadata

Authors
Buscail, L., Bournet, B., & Cordelier, P.
Affiliations
Université Toulouse III - Paul Sabatier (FR)
Corresponding author
Buscail, Louis
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2020-01-31
Volume
17
Issue
3
Pages
153-168
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3003574401
Cited by
721
References
202
Citations by year
2026: 70 · 2025: 103 · 2024: 134 · 2023: 121 · 2022: 153 · 2021: 106 · 2020: 34
FWCI
11.37
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
KRAS mutation, pancreatic ductal adenocarcinoma, pancreatic cancer diagnosis, prognosis, liquid biopsy, KRAS mutation testing, fine-needle aspiration, cytopathology, serum biomarkers, KRAS-targeted therapy
MeSH terms
Animals, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41575-019-0245-4
The paper
Buscail, L., Bournet, B., & Cordelier, P. (2020). Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-019-0245-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.